Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fcγ Receptors on Macrophages
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Trastuzumab has been used for the treatment of HER2-overexpressing breast cancer for more than a decade, but the mechanisms of action for the therapy are still being actively investigated. Ab-dependent cell-mediated cytotoxicity mediated by NK cells is well recognized as one of the key mechanisms of action for trastuzumab, but trastuzumab-mediated Ab-dependent cellular phagocytosis (ADCP) has not been established. In this study, we demonstrate that macrophages, by way of phagocytic engulfment, can mediate ADCP and cancer cell killing in the presence of trastuzumab. Increased infiltration of macrophages in the tumor tissue was associated with enhanced efficacy of trastuzumab whereas depletion of macrophages resulted in reduced antitumor efficacy in mouse xenograft tumor models. Among the four mouse FcγRs, FcγRIV exhibits the strongest binding affinity to trastuzumab. Knockdown of FcγRIV in mouse macrophages reduced cancer cell killing and ADCP activity triggered by trastuzumab. Consistently, an upregulation of FcγRIV expression by IFN-γ triggered an increased ADCP activity by trastuzumab. In an analogous fashion, IFN-γ priming of human macrophages increased the expression of FcγRIII, the ortholog of murine FcγRIV, and increased trastuzumab-mediated cancer cell killing. Thus, in two independent systems, the results indicated that activation of macrophages in combination with trastuzumab can serve as a therapeutic strategy for treating high HER2 breast cancer by boosting ADCP killing of cancer cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HER2-targeting mAbs also elicit antibody-dependent cellular phagocytosis (ADCP), involving the clearance of antibodybound tumor cells by macrophages (Shi et al., 2015), a phenomenon that may be accompanied by macrophage polarization towardanM2-like immunosuppressive phenotype (Su et al., 2018).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Shi et al., 2015
In the citing paper
“induction of ADCP of HER2-expressing cancer cells”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Shi et al., 2015
Citations
Cites
2 retracted
She, Q.-B., Chandarlapaty, S., Ye, Q., Lobo, J., Haskell, K. M., Leander, K. R., DeFeo-Jones, D., Huber, H. E., & Rosen, N. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003065 · Cited by 301 · cited 1×
“Other mechanisms of action of trastuzumab, including downregulation of HER2 expression (6) and inhibition of HER2 oncogenic signaling (2, 4), might also be involved.”
BackgroundRetractedKohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W.-K., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226 · cited 1×
“Therefore, antitumor efficacy of trastuzumab in the mouse group with macrophage depletion by clodrosome might be contributed by an NK cell– mediated ADCC effect, as ADCC as a mechanism of action for trastuzumab was reported previously (27, 29).”
BackgroundRetractedInhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“Studies have shown that mice with Fcg-chain knockout (g) or knockout of individual activating FcgRs lost immune effector functions of Abs and resulted in reduced antitumor efficacy of trastuzumab (22, 32, 33).”
BackgroundNagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 1×
“Other mechanisms of action of trastuzumab, including downregulation of HER2 expression (6) and inhibition of HER2 oncogenic signaling (2, 4), might also be involved.”
BackgroundDivergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding
Nimmerjahn, F., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1118948 · Cited by 1,037 · cited 1×
“It has been shown that FcgRIV is important in mediating the function of anticancer Ab (IgG2a) in the model of lung and liver metastases using murine melanoma cells, and in an anti-CD20 Abdependent B cell depletion model (24, 36, 37).”
BackgroundMusolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981 · cited 1×
“Clinical studies have implicated the important role of FcgRIII in trastuzumab efficacy (38), even though function of FcgRIII on NK cells is considered mainly to contribute to cancer cell killing through ADCC (39).”
BackgroundBone Marrow-Derived Macrophages (BMM): Isolation and Applications
Weischenfeldt, J., & Porse, B. (2008) · Cold Spring Harbor Protocols · doi:10.1101/pdb.prot5080 · Cited by 955 · cited 2×
“Briefly, the isolated bone marrow cells were cultured in complete RPMI 1640 medium supplemented with 10% FCS and 30% pretested conditioned medium from the L929 cell line as a source of M-CSF for 5 d (17).”
BackgroundMethodEngineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 803 · cited 1×
“In this study, we demonstrated that activated macrophages readily phagocytosed trastuzumab-coated cancer cells (ADCP) and mediated Ab-dependent cancer cell killing in coculture conditions in vitro, and the results are consistent with the study reported previously (16).”
ResultFcγRIV: A Novel FcR with Distinct IgG Subclass Specificity
Nimmerjahn, F., Bruhns, P., Horiuchi, K., & Ravetch, J. V. (2005) · Immunity · doi:10.1016/j.immuni.2005.05.010 · Cited by 660 · cited 4×
“FcgRIV binds to mouse IgG2a and IgG2b with intermediate affinity, but it has no detectable binding to mouse IgG1 or IgG3 (22).”
BackgroundInfluentialThe function of Fcγ receptors in dendritic cells and macrophages
Guilliams, M., Bruhns, P., Saeys, Y., Hammad, H., & Lambrecht, B. N. (2014) · Nature Reviews Immunology · doi:10.1038/nri3582 · Cited by 639
Cited by
Items 201–202 of 202
Ju, M., Zhang, M., Ma, S., An, Y., Xiao, S., Xu, J., Li, N., Chen, Y., Wei, M., Wang, H., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.10.003
Receptor-Targeted mAbs in Solid Tumors (EGFR/HER2 Family)
Cardoso, A., & Machado, S. (2026) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-3373-6551-0.ch009
Metadata
- Authors
- Shi, Y., Fan, X., Deng, H., Brezski, R. J., Rycyzyn, M., Jordan, R. E., Strohl, W. R., Zou, Q., Zhang, N., & An, Z.
- Affiliations
- Army Medical University (CN)
- Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (US)
- Janssen Research & Development (United States) (US)
- Corresponding author
- Shi, Yun
- Fan, Xuejun
- Deng, Hui
- Zhang, Ningyan
- An, Zhiqiang
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-05-01
- Volume
- 194
- Issue
- 9
- Pages
- 4379-4386
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1589766395
- Cited by
- 195
- References
- 40
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 22 · 2023: 19 · 2022: 27 · 2021: 23 · 2020: 20 · 2019: 16 · 2018: 13 · 2017: 19 · 2016: 6 · 2015: 3
- FWCI
- 11.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- trastuzumab, HER2-positive breast cancer, antibody-dependent cellular phagocytosis, macrophages, Fc gamma receptor, FcγRIV, FcγRIII, interferon-gamma, macrophage activation, tumor-associated macrophages, phagocytic killing, antitumor immunity
- MeSH terms
- Trastuzumab, Animals, Antibody-Dependent Cell Cytotoxicity, Antineoplastic Agents, Cytotoxicity, Immunologic, Disease Models, Animal, Humans, Macrophages, Neoplasms, Phagocytosis, Gene Expression, Receptors, IgG, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Cell Line, Tumor, Mice, Antibodies, Monoclonal, Humanized, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.